Immatics’ CAR T-Cell Therapy Delivers Strong, Durable Responses in Metastatic Uveal Melanoma

HOUSTON, TX & TUERINGEN, GERMANY — October 20, 2025 — Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company, today announced highly encouraging, mature data for its PRAME-targeting cell therapy, anzu-cel (anzutresgene autoleucel), in patients with metastatic uveal melanoma. The updated results from the ongoing Phase 1b trial demonstrate robust and durable clinical benefit, prompting the immediate initiation of a Phase 2 cohort for this high-need indication.

The data, involving 16 heavily pre-treated patients, were presented at the European Society for Medical Oncology (ESMO) Congress 2025 during the Presidential Symposium III.

Strong Durability and Response in Difficult-to-Treat Cancer

Metastatic uveal melanoma is a difficult-to-treat cancer with a poor prognosis and limited therapeutic options. Anzu-cel, a PRAME-directed TCR T-cell therapy, showed significant and sustained anti-tumor activity across the patient cohort.

Anti-tumor activity was observed across various metastatic sites, including the liver (which was involved in 81% of patients). Treatment led to a median shrinkage of 49.6% in liver target lesion size. Importantly, strong responses were observed even in patients who had previously received other TCR-based therapies.

“The results with anzu-cel presented today signal a much-needed breakthrough for patients with metastatic uveal melanoma,” said Sapna Patel, M.D., Professor of Medicine, University of Colorado Cancer Center, who presented the data.

Favorable Tolerability and Expansion into Phase 2

Anzu-cel maintained a favorable tolerability profile generally consistent with its profile in other cancer types. The most frequent side effects were manageable cytopenias and cytokine release syndrome (CRS), which was predominantly Grade 1 or 2 and resolved quickly. No anzu-cel-related Grade 5 (fatal) events were observed.

Based on the promising activity, Immatics has initiated a Phase 2 cohort for metastatic uveal melanoma, planning to enroll approximately 30 patients in the U.S. and Germany. Given the high prevalence of the PRAME target in this cancer, prospective PRAME testing will no longer be required for inclusion in the trial, streamlining patient access.

Cedrik Britten, M.D., Chief Medical Officer at Immatics, stated, “The continued strong clinical data presented today reinforce our conviction in maximizing the potential of our PRAME cell therapy, anzu-cel, and expanding its development into metastatic uveal melanoma, a rare cancer with very high unmet medical need.”

Anzu-cel is currently also being evaluated in the registration-enabling Phase 3 SUPRAME trial for unresectable or metastatic cutaneous melanoma.